FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma By Ogkologos - July 18, 2025 536 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR “After a fire and a pandemic, it felt amazing to finish... November 1, 2021 When Cancer Spreads to Bone, A Single Dose of Radiation Therapy... May 21, 2019 No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In... November 17, 2025 GENIE Registry Identifies Cancer Types Enriched with KRASG12C Somatic Mutations January 18, 2021 Load more HOT NEWS WHO’s plans to create a ‘cervical cancer-free future’ SBRT Emerging as an Important Treatment for Early-Stage Kidney Cancer RANO and Modified RANO Criteria Demonstrate Similar Correlations Between PFS and... What People With Breast Cancer and Survivors Should Know About Exercising...
